Delivery Order SPE2DB22D1017-SPE2DB25FYSCW
- Not listed
- The Defense Logistics Agency awarded a $28,730.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $26,755.07 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 18, 2025, with completion expected by June 20, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award issued under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $13,565.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,099.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) on September 9, 2025, with completion scheduled for September 10, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of RINVOQ ER 15 mg tablets (30-unit packages) valued at $34,723.92. This is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and represents a competitive award with no set-aside designation. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $16,470.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (quantity: 30 units) on September 19, 2025, with completion targeted for September 22, 2025. The award, which carries no set-aside designation, represents a competitive delivery order against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYSCWDelivery Order
The Defense Logistics Agency awarded a $29,343.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 26, 2025, with an ultimate completion date of September 29, 2025. This competitively awarded, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate operations as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The underlying IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a comprehensive range of medications, medical supplies, and specialty pharmaceuticals to support military healthcare programs and other federal health systems, including the Defense Health Agency and U.S. Coast Guard. RINVOQ ER (upadacitinib extended-release), a specialty medication used in treating inflammatory conditions, aligns with AmerisourceBergen's established portfolio of specialty and brand-name pharmaceutical deliveries under the DLA Troop Support contract structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.3k | 9/26/25 |